

## Ogawa, Katelyn

---

**From:** Richard A. Van Etten, MD, PhD, Director, Chao Family Comprehensive Cancer Center  
<hsmarcom@uci.edu>  
**Sent:** Thursday, September 22, 2022 11:00 AM  
**To:** Ogawa, Katelyn  
**Subject:** Cancer clinical trials open to patients



The UCI Health Chao Family Comprehensive Cancer Center is now enrolling patients in these featured clinical trials.

To refer a patient or get more information about a clinical trial, click on the principal investigator's name to send an email. You may also contact us at [ucstudy@uci.edu](mailto:ucstudy@uci.edu) or [877-UC-Study](tel:877-UC-Study). To search all cancer clinical trials now available at UCI Health, visit [cancer.uci.edu/clinical-trials-flowcharts](https://cancer.uci.edu/clinical-trials-flowcharts)

### **Brain and nervous system**

A phase 2 trial of SMO/AKT/NF2/CDK inhibitors in progressive meningiomas with SMO/AKT/NF2/CDK pathway mutations (Alliance-A071401)

*For more information, contact principal investigator Daniela Bota, MD*

A phase 2 study of the PARP inhibitor olaparib (AZD2281) in IDH1- and IDH2-mutant advanced solid tumors (ETCTN-10129)

*For more information, contact principal investigator Xiao-Tang Kong, MD*

### **Breast**

A randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple-negative breast cancer (ETCTN-10146)

*For more information, contact principal investigator Ritesh Parajuli, MD*

A phase 3 clinical trial evaluating de-escalation of breast radiation for conservative

treatment of stage I, hormone-sensitive, HER2-negative breast cancer with an onco-type recurrence score of less than or equal to 18 (DEBRA) (NRG-B007)

*For more information, contact principal investigator Rita Mehta, MD*

## **Gastrointestinal**

A phase 2, single-arm study of M6620 in combination with irinotecan in patients with progressive TP53-mutant gastric and gastroesophageal junction cancer (ETCTN-10211)

*For more information, contact principal investigator Farshid Dayyani, MD*

A phase 1B/3 study of bemarituzumab + chemotherapy and nivolumab vs. chemotherapy and nivolumab alone in subjects with previously untreated advanced gastric and gastroesophageal junction cancer with FGFR2b overexpression (UCI-21-193/20210098)

*For more information, contact principal investigator Farshid Dayyani, MD*

## **Genitourinary**

A phase 3, randomized, comparator-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in combination with bacillus Calmette-Guérin (BCG) in participants with high-risk, non-muscle invasive bladder cancer (HR-NMIBC) that is either persistent or recurrent following BCG induction or is naïve to BCG treatment (KEYNOTE-676) (NCT03711032) (UCI-18-53)

*For more information, contact principal investigator Edward Uchio, MD*

An open-label, randomized, phase 3 study comparing 177Lu-PSMA-617 in combination with standard of care vs. standard of care alone in adult male patients with metastatic, hormone-sensitive prostate cancer (mHSPC) (PSMAddition) (UCI-21-83/CAAA617C12301)

*For more information, contact principal investigator Arash Rezazadeh Kalebasty, MD*

A randomized phase 2 trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer, where cisplatin-based treatment is not an option (ETCTN-10100)

*For more information, contact principal investigator Nataliya Mar, MD*

## **Gynecologic oncology**

Groningen international study on sentinel nodes in vulvar cancer (GROINSS-V) III: a prospective phase 2 treatment trial (NRG-GY024)

*For more information, contact principal investigator Krishnansu Tewari, MD*

A phase 1b/2 study of TAK-981 + pembrolizumab to evaluate the safety, tolerability and antitumor activity of the combination in patients with select advanced or metastatic solid tumors (UCI-20-110/TAK-981-1502)

*For more information, contact principal investigator Krishnansu Tewari, MD*

## **Head and neck**

Randomized phase 2 and phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) (HN001)

*For more information, contact principal investigator Rupali Nabar, MD*

A phase 2, open-label, multicenter study of PDS0101 and pembrolizumab (KEYTRUDA®) combination immunotherapy in subjects with recurrent and/or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection (UCI-21-107/PDS0101-HNC-201)

*For more information, contact principal investigator Edward Nelson, MD*

## **Hematologic malignancies**

An open-label, multicenter, nonrandomized phase 1 dose-escalation study to investigate the safety, tolerability, pharmacokinetics and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell lymphoma (UCI-21-99/ONO-4685-03)

*For more information, contact principal investigator Lauren Pinter-Brown, MD*

A randomized, open-label, phase 3 trial of epcoritamab vs. investigator's choice chemotherapy in relapsed/refractory diffuse large B-cell lymphoma (UCI-21-60/GCT3013-05)

*For more information, contact principal investigator Elizabeth Brém, MD*

## **Hepatobiliary**

A phase 1 study of anetumab ravtansine in combination with either anti-PD-1 antibody or anti-CTLA4 and anti-PD-1 antibodies, or anti-PD-1 antibody and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (ETCTN-10208)

*For more information, contact principal investigator Farshid Dayyani, MD*

A randomized phase 2 trial of postoperative adjuvant capecitabine and temozolomide vs. observation in high-risk pancreatic neuroendocrine tumors (SWOG-S2104)

*For more information, contact principal investigator Jennifer Valerin, MD*

## **Lung**

A phase 1b/2 master protocol of agents targeting the mitogen-activated protein kinase pathway in patients with advanced non-small cell lung cancer (HERKULES-2) (UCI-21-63/ERAS-007-02)

*For more information, contact principal investigator Misako Nagasaka, MD*

A phase 1a/1b dose-escalation and dose-expansion study evaluating the safety, pharmacokinetics, and activity of GDC-6036 as a single agent and in combination with other anticancer therapies in patients with advanced or metastatic solid tumors with a KRAS G12C mutation (UCI-20-141/GO42144)

*For more information, contact principal investigator Misako Nagasaka, MD*

## **Skin**

A phase 2 study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T-cell and NK-cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma and other rare skin tumors (ETCTN-10057)

*For more information, contact principal investigator Maki Yamamoto, MD*

A phase 2, open-label, dose-finding study to determine the optimal dose for lymph node visualization using ASP5354 in participants with breast cancer or melanoma undergoing sentinel lymph node biopsy (UCI-21-106/5354-CL-1201)

*For more information, contact principal investigator Jeremy Phillip Harris, MD*



As an NCI-designated comprehensive cancer center, the Chao Family Comprehensive Cancer Center conducts many clinical trials. By participating in a clinical trial, patients have access to leading-edge treatments and therapies long before they are available to the general public. According to the National Comprehensive Cancer Network (NCCN) guidelines, the best management for many cancer patients is on a clinical trial.

UCI Medical Center | 101 The City Drive South | Orange, CA 92868

09/22